Quick Takeaways
- Newtyn Management, LLC filed SCHEDULE 13G/A for Theravance Biopharma, Inc. Ordinary Share $0.00001 par value (TBPH).
- Disclosed ownership: 8.5%.
- Date of event: 31 Dec 2025.
Newtyn Management, LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Theravance Biopharma, Inc. Ordinary Share $0.00001 par value (TBPH)
- Filing Manager
- Newtyn Management, LLC
- Reporting Manager
- Newtyn Management, LLC
- Symbol
- TBPH
- Shares outstanding
- 50,588,235 shares
- Disclosed Ownership
- 4,300,000 shares
- Ownership
- 8.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:15:25 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Newtyn Management, LLC disclosed 8.5% ownership in Theravance Biopharma, Inc. Ordinary Share $0.00001 par value (TBPH) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 17 Feb 2026, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Newtyn Management, LLC | 8.5% | 4,300,000 | 4,300,000 | 0 | /s/ Eugene Dozortsev | Eugene Dozortsev, Authorized Signatory | |
| Newtyn TE Partners, LP | 5.3% | 2,678,900 | 2,678,900 | 0 | /s/ Eugene Dozortsev | Eugene Dozortsev, Authorized Signatory of Newtyn Management, LLC, the Investment Manager |